Navigation Links
Enzyvant to Develop Novel Biologic Therapy for Complete DiGeorge Syndrome
Date:1/6/2017

BASEL, Switzerland, Jan. 6, 2017 /PRNewswire/ -- Enzyvant, a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases, today announced entering into an exclusive worldwide licensing agreement with Duke University to develop RVT-802, a tissue-based therapy for the treatment of complete DiGeorge Syndrome (cDGS), a rare and fatal congenital immunodeficiency disease. In the absence of treatment, children born with cDGS typically succumb to infections within the first two years of life due to their severe immunodeficiency.

"Patients with complete DiGeorge Syndrome lack effective treatment options, but this novel program offers the hope of a life-saving solution," said Chief Executive Officer Dr. Alvin Shih. "It is our responsibility to ensure that the children with this disease who need this treatment are able to receive it."

Under the terms of the agreement, data from Duke's experience will be used to support submission of a Biologics License Application (BLA) with the Food and Drug Administration (FDA) for approval. RVT-802 expands Enzyvant's pipeline of potentially transformative biologic therapies for rare genetic diseases with high unmet need.

Dr. M. Louise Markert, Professor of Pediatrics at Duke University, has led research on the treatment of immunodeficiency in patients with cDGS. The findings of Dr. Markert and her research team have been published in the New England Journal of Medicine as well as numerous other peer-reviewed scientific journals and clinical publications. "This is an encouraging development for the patients and parents confronting this disease," said Dr. Markert. "I look forward to working with Enzyvant to make this life-saving therapy more available to babies who so desperately need it."

About Complete DiGeorge Syndrome

Complete DiGeorge Syndrome (cDGS) represents approximately one percent of all patients with DiGeorge Syndrome, a congenital immunodeficiency disease. The three main characteristics of cDGS are congenital heart disease, hypoparathyroidism (leading to low calcium levels), and athymia (lack of thymus tissue). Athymia leads to severe immunodeficiency due to the inability to produce normally functioning T cells, which defend against infection and regulate essential processes in the immune system. cDGS is uniformly fatal if untreated, with death typically occurring in the first two years of life due to susceptibility to infection.

About RVT-802

RVT-802 is a biologic therapy that was initially developed by Dr. Markert and her colleagues using proprietary processes to harvest, culture, and apply allogeneic thymic tissue for the treatment of primary immune deficiency resulting from cDGS. Preliminary clinical results suggest a survival rate of over 70% for treated patients. RVT-802 has been granted orphan drug designation by the FDA and Enzyvant anticipates a potential BLA filing in 2018.

About Enzyvant

Enzyvant is a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases. Enzyvant is currently preparing a clinical trial of RVT-801, an investigational enzyme replacement therapy for the treatment of acid ceramidase deficiency (ACD), a rare lysosomal storage disease which manifests as Farber disease. Enzyvant is also planning to advance the development of RVT-802, an investigational biologic therapy for complete DiGeorge Syndrome. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.

Related Links
http://www.enzyvant.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/enzyvant-to-develop-novel-biologic-therapy-for-complete-digeorge-syndrome-300386922.html


'/>"/>
SOURCE Enzyvant
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Guardant Health to create a new 500-plus-gene liquid biopsy panel with several leading pharmaceutical companies to accelerate clinical trials and drug development
2. Menlo Therapeutics Recruits Experienced Management Team and Board Leadership to Accelerate Development of Serlopitant for Treatment of Pruritus
3. Eisai Acquires All Global Development And Marketing Rights For Chronic Weight Management Treatment Lorcaserin HCI
4. Global Transdermal Prescription Gels Market: Essential Formulation Factors, Technologies and Market Development - Research and Markets
5. ImmuNext Enters into a Strategic Alliance to Develop Novel Therapies for Autoimmune Diseases
6. Global Diagnostic Imaging Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Type, by End User
7. Global Ultrasound Device Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Type, by Portability, by Display, by Technology, by Application
8. Global Neurostimulation Device Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Type, and by Application
9. Global Enteral Nutrition Market Size, Share, Development, Growth and Demand Forecast to 2022 - Industry Insights by Type
10. Daiichi Sankyo and DarwinHealth Announce Strategic Partnership to Deploy a Quantitative Systems Biology Discovery Platform to Prioritize Daiichi Sankyo Cancer Enterprise Compounds for Development
11. Sun Pharma & Moebius Medical Sign Exclusive Global Licensing Deal to Develop Novel Liposomal Non-opioid Pain Product for Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... 2019 , ... Uniform Advantage (UA), a leader in the apparel ... Cancer programs and services. , This year, more than 271,000 Americans will be diagnosed ... month of October 2019, Uniform Advantage will donate $5 for every unique use of ...
(Date:9/17/2019)... WALTHAM, Mass. (PRWEB) , ... September 17, 2019 ... ... the long-term care industry, announces today the launch of RegistryConnect , the ... the input of registry owners. RegistryConnect includes care-matching, schedule recording, client and caregiver ...
(Date:9/17/2019)... ... 2019 , ... Scientists writing in a 2017 issue of ... progressive destruction of joint cartilage in osteoarthritis are “on the close horizon.” ... orthopedic surgeon Alejandro Badia, MD , founder and chief medical officer of ...
Breaking Medicine Technology:
(Date:9/22/2019)... ... September 21, 2019 , ... Dr. Perry ... certified by the American Academy of Facial Esthetics (AAFE) to administer dermal filler ... products. , Dr. Patel has also been certified by the AAFE to administer ...
(Date:9/22/2019)... Ala. (PRWEB) , ... September 22, 2019 , ... On ... drugs, according to the Centers for Disease Control and Prevention. The Baldwin County Community ... incinerator -- on Monday, Sept. 23, at 10 a.m. at the Daphne Police Department ...
(Date:9/18/2019)... ... September 18, 2019 , ... DOROT hosts its annual Rosh Hashanah Package delivery on Sunday, ... 700 volunteers will be heading out to visit our seniors. , , ... Upper East Side, at Central Synagogue 123 East 55st Street , & Westchester ...
(Date:9/18/2019)... ... September 18, 2019 , ... NJ Top Dentists has reviewed ... specializes in general and cosmetic dentistry at his practice located in Matawan, New ... quality dental care over the past seven decades. , Services provided by Dr. ...
(Date:9/17/2019)... ... September 17, 2019 , ... National University ... the American Heart Association (AHA)-San Diego Chapter to raise awareness of heart health. ... on Saturday, September 21 in Balboa Park alongside National University System Chancellor and ...
Breaking Medicine News(10 mins):